Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod

Antiviral Research

Volumn 44, Issue 1, 1999, Pages 31-42

  Miller, Richard L ^a   Imbertson, Linda M ^a   Reiter, Michael J ^a   Gerster, John F ^a  

^a 3M COMPANY   (United States)

Author keywords

Guinea pig; HSV infection; Imiquimod; Immune response modifier; R 837

Indexed keywords

ACICLOVIR; IMIQUIMOD; METHOXYFLURANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; GUINEA PIG; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; INTRAVAGINAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

AMINOQUINOLINES; ANIMALS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; INTERFERON INDUCERS; MOLECULAR STRUCTURE; VERO CELLS;

ANIMALIA; CAVIA; CAVIA PORCELLUS; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS; SUS SCROFA;

EID: 0032728998     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00052-2     Document Type: Article

References (36)

1. Augerbraun M., Feldman J., Chirgwin K., Zenilman J., Clarke L., DeHovitz J., Landesman S., Minkoff H. Increased genital shedding of herpes simplex virus type 2 in HIV- seropositive women. Ann. Int. Med. 123:1995;845-847.
2. Bernstein D.I., Harrison C.J. Effects of the immunomodulating agent R-837 on acute and latent herpes simplex virus type 2 infections. Antimicrob. Agents Chemother. 33:1989;1511-1515.
3. Bernstein D.I., Miller R.L., Harrison C.J. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea pigs when begun after lesion development. Antiviral Res. 20:1993;45-55.
4. Bernstein D.I., Miller R.L., Harrison C.J. Adjuvant effects on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis. 167:1993;731-735.
5. Bernstein D.I., Harrison C.J., Tepe E.R., Shahwan A., Miller R.L. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine. 13:1995;72-76.
6. Burns W.H., Saral R., Santos G.W., Laskin O.L., Lietman P.S., McLaren C., Barry D.W. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. Lancet. 1:1982;421-423.
7. Cardamakis E., Relakis K., Kotoulas I.-G., Michopoulos J., Metallinos K., Mantouvalos H., Tzingounis V. Treatment of recurrent genital herpes with interferon alpha-2a. Gynecol. Obstet. Invest. 46:1998;54-57.
8. Chatis P.A., Crumpacker C.S. Analysis of the thymidine kinase gene from clinically isolated ayclovir-resistant herpes simplex viruses. Virology. 180:1991;793-797.
9. Christensen B., Hengge U.R. Recurrent urogenital herpes simplex-successful treatment with imiquimod? Sexually Transmitted Infect. 75:1999;132-133.
10. Coen D., Shaffer P. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA. 77:1980;2265-2269.
11. Darby G., Field H.J., Salisbury S.A. Altered substrate specificity of herpes simplex thymidine kinase confers acyclovir resistance. Nature (London). 289:1981;81-83.
12. De Miranda P., Krasny H.C., Page D.A., Elion G.B. The disposition of acyclovir in different species. J. Pharmacol. Exp. Ther. 219:1981;309-315.
13. Douglas J.M., Critchlow C., Benedetti J., Mertz G.J., Connor J.D., Hintz M.A., Fahnlander A., Remington M., Winter C., Corey L.A. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex infection. New Engl. J. Med. 310:1984;1551-1556.
14. Erlich S.K., Mills J., Chatis P. Acyclovir resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. New Engl. J. Med. 320:1988;293-296.
15. Fleming D.T., McQuillan G.M., Johnson R.E., Nahmais A.J., Aral S.O., Lee F.K., Louis M.E. Herpes simplex virus type 2 in the United States, 1976 to 1994. New Engl. J. Med. 337:1997;1105-1111.
16. Harrison C.J., Jenski L., Voychehovski T., Bernstein D.I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 10:1988;209-224.
17. Harrison C.J., Stanberry L.R., Bernstein D.I. Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs. Antiviral Res. 15:1991;315-322.
18. Harrison C.J., Miller R.L., Bernstein D.I. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicro. Agents Chemother. 38:1994;2059-2064.
19. Holmberg S.D., Stewart J.A., Gerber A.R. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. J. Am. Med. Assoc. 259:1988;1048-1050.
20. Imbertson L.M., Beurline J.M., Couture A.M., Gibson S.J., Smith R.M., Miller R.L., Reiter M.J., Wagner T.L., Tomai M.A. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. 110:1998;734-739.
21. Kende M., Rill W.L., Contos M.J., Canonico P.G. Efficacy of a novel orally active immunomodulator, S-26308 against arbovirus infections. Antivir. Res. 9:1988;88.
22. Kerr I.M., Stark G.R. The antiviral effects of the interferons and their inhibition. J. Interferon Res. 12:1992;237-240.
23. King, D.H., Galasso, G. (1982) Proceedings of a symposium on acyclovir. Am. J. Med. 73 (1A), 1-392.
24. Koelle D.M., Frank J.M., Johnson M.L., Kwok W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T-cells infiltrating human genital herpes lesions. J. Virol. 72(9):1998;7476-7483.
25. Kost R.G., Hill E.L., Tigges M., Straus S.E. Brief report: recurrent acyclovir resistant genital herpes in an immunocompetent patient. New Engl. J. Med. 329:1993;1777-1782.
26. Miller, R.L., Imbertson, L.I., Reiter, M.J., Schwartzmiller, D.H., Pecore, S.E., Gerster, J.F. (1985) Inhibition of herpes simplex virus infection in a guinea pig model by S-26308. In: Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Minneapolis, Minnesota.
27. Miller, R.L., Imbertson, L.M., Reiter,M.J., Pecore, S.E., Gerster, J.F. (1986) Interferon induction by antiviral S-26308 in guinea pigs. In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, New Orleans, Louisiana.
28. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. A review of imiquimod applied topically: a novel immune response modifier and new class of drug. Intl. J. Immuno Pharmacol. 21:1999;1-14.
29. Posavad C.M., Koelle D.M., Shaughnessy M.F., Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc. Nat. Acad. Sci. USA. 94:1997;10289-10294.
30. Safrin S., Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrobial Agents Chemother. 37:1993;2241-2243.
31. Schacker T., Zeh J., Hu H.L., Hill E., Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J. Infect. Dis. 178(6):1998;1616-1622.
32. Shupack J., Stiller M., Knobler E., Ackerman C., Jondreau L., Kenny C. Topical alpha-interferon in recurrent genital herpes simplex infection. Dermatologic. 181:1990;134-138.
33. Slade H.B., Owens M.L., Tomai M.A., Miller R.L. Imiquimod 5% cream (Aldara™). Exp. Opin. Invest. Drugs. 7(3):1998;437-449.
34. Stanberry L.R., Kern E.R., Richards J.T., Abbott T.M., Overall J.C. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Inf. Dis. 146:1982;397-404.
35. Tyring S.K., Arany I., Stanley M.A., Tomai M.A., Miller R.L., Smith M.H., McDermott D.J., Slade H.B. A randomized, controlled, molecular study of Condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 178:1998;551-555.
36. Wagner T.L., Ahonen C.L., Couture A.M., Gibson S.J., Miller R.L., Smith R.M., Reiter M.J., Vasilakos J.P., Tomai M.A. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cellular Immunology. 191:1999;10-19.